Sanofi Net Profit Margin 2010-2023 | SNY
Current and historical net profit margin for Sanofi (SNY) from 2010 to 2023. Net profit margin can be defined as net Income as a portion of total sales revenue. Sanofi net profit margin for the three months ending December 31, 2023 was .
| Sanofi Net Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Net Income |
Net Margin |
| 2023-12-31 |
$50.27B |
$5.84B |
11.63% |
| 2023-09-30 |
$49.01B |
$9.68B |
19.75% |
| 2023-06-30 |
$48.42B |
$9.02B |
18.63% |
| 2023-03-31 |
$48.20B |
$8.71B |
18.06% |
| 2022-12-31 |
$47.82B |
$8.82B |
18.44% |
| 2022-09-30 |
$48.72B |
$8.33B |
17.09% |
| 2022-03-31 |
$34.76B |
$6.88B |
19.78% |
| 2021-09-30 |
$35.03B |
$6.90B |
19.70% |
| 2021-03-31 |
$43.57B |
$7.99B |
18.34% |
| 2020-09-30 |
$42.75B |
$7.39B |
17.29% |
| 2020-03-31 |
$41.19B |
$6.36B |
15.44% |
| 2019-09-30 |
$41.49B |
$4.98B |
12.00% |
| 2019-03-31 |
$41.50B |
$4.86B |
11.70% |
| 2018-03-31 |
$41.43B |
$4.71B |
11.36% |
| 2017-12-31 |
$40.92B |
$9.53B |
23.30% |
| 2017-09-30 |
$40.25B |
$9.90B |
24.58% |
| 2017-06-30 |
$39.59B |
$9.92B |
25.06% |
| 2017-03-31 |
$39.14B |
$10.09B |
25.77% |
| 2016-12-31 |
$38.41B |
$5.21B |
13.57% |
| 2016-09-30 |
$39.27B |
$6.19B |
15.75% |
| 2016-06-30 |
$39.37B |
$5.76B |
14.63% |
| 2016-03-31 |
$41.16B |
$5.52B |
13.40% |
| 2015-09-30 |
$42.97B |
$4.90B |
11.40% |
| 2015-06-30 |
$43.92B |
$4.59B |
10.45% |
| 2014-06-30 |
$44.70B |
$5.57B |
12.45% |
| 2013-06-30 |
$45.22B |
$6.39B |
14.12% |
| 2012-06-30 |
$46.75B |
$8.61B |
18.41% |
| 2012-03-31 |
$47.10B |
$8.56B |
18.17% |
| 2011-12-31 |
$47.27B |
$9.33B |
19.74% |
| 2011-09-30 |
$45.65B |
$8.04B |
17.61% |
| 2011-06-30 |
$44.35B |
$7.45B |
16.81% |
| 2011-03-31 |
$42.93B |
$8.22B |
19.15% |
| 2010-12-31 |
$41.26B |
$8.24B |
19.96% |
| 2010-09-30 |
$41.28B |
$9.30B |
22.53% |
| 2010-06-30 |
$41.42B |
$10.37B |
25.04% |
| 2010-03-31 |
$41.35B |
$11.38B |
27.52% |
| 2009-12-31 |
$40.79B |
$10.99B |
26.95% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$117.905B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
